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oes Rhythm Control
mprove Functional Status in
atients With Atrial Fibrillation?*
dward P. Gerstenfeld, MD, FACC
hiladelphia, Pennsylvania
umerous nonpharmacologic therapies for treating atrial
brillation (AF) continue to dominate scientific conferences
nd the literature. However, most clinicians still spend the
ost of their time debating the risks and benefits of a rate
ersus rhythm control strategy for managing patients with
F. Several small randomized studies, such as Rate Control
ersus Electrical Cardioversion (RACE) (1), Pharmacolog-
cal Intervention in Atrial Fibrillation (PIAF) (2), and
trategies of Treatment of Atrial Fibrillation (STAF) (3),
id not find a mortality benefit to the maintenance of sinus
hythm. The landmark Atrial Fibrillation Investigation of
hythm Management (AFFIRM) (4) trial was designed to
See page 1891
efinitively address this most pervasive question—whether
aintaining sinus rhythm had any mortality benefit over
imply leaving patient in AF and controlling the ventricular
ate. When the main results of AFFIRM trial demonstrated
o mortality benefit to a rhythm control strategy, many
nticipated the demise of antiarrhythmic drug therapy for
F. Yet, the AFFIRM trial had several limitations and left
any questions unanswered. Approximately one-third of
FFIRM trial patients were enrolled after their first episode
f AF, a group who would rarely be treated with antiar-
hythmic drugs in clinical practice. In addition, many of the
atients enrolled were elderly and either asymptomatic or
nly minimally symptomatic. Finally, by the end of the
tudy, only 63% of those assigned randomly to a rhythm
ontrol strategy maintained sinus rhythm, whereas one-
hird of patients in the rate control arm were in sinus
hythm. Therefore, one must interpret the AFFIRM trial as
omparing a strategy of rate control compared with a
trategy of rhythm control, knowing that these goals were
ot fully achieved.
Several follow-up AFFIRM studies have attempted to
ddress some of these limitations. In a survival substudy by
orley et al. (5), an on-treatment analysis found that
aintaining sinus rhythm was an independent predictor of
urvival. This was the first study to find a survival advantage
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.g
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r. Gerstenfeld is supported in part by an AHA Scientist Development Grant.o maintenance of sinus rhythm, although this analysis was
ost-hoc, and it is always difficult to exclude the possibility
hat the maintenance of sinus rhythm is just a marker of
mproved health. Interestingly, the survival benefit of main-
aining sinus rhythm seemed to be offset by an increased
ortality risk of antiarrhythmic drug therapy. This supports
he concept that the main reason to initiate antiarrhythmic
rug therapy in patients with AF is to control symptoms.
ome often ask why one should pursue an aggressive
herapy to maintain sinus rhythm when AF is not a
ife-threatening arrhythmia. However, AF can cause a wide
ange of symptoms in many patients. In one study, the
uality of life of patients with AF was similar to a group of
atients with chronic heart failure (6). Maintenance of sinus
hythm in these patients can have a large impact on a
atient’s functional status and quality of life.
In this issue of the Journal, Chung et al. (7) present a
ubstudy of the AFFIRM trial that addresses an important
uestion—whether use of antiarrhythmic drugs to maintain
inus rhythm affects exercise tolerance or New York Heart
ssociation (NYHA) functional class compared with a rate
ontrol strategy. On the basis of previous studies showing a
igh rate of silent cerebral infarctions in patients with AF
8,9), the investigators also assessed mental status in both
roups using a mini-mental status examination. A prospec-
ively defined subgroup of the AFFIRM trial comprising
45 patients underwent a 6-min walk and mini-mental
tatus examination at baseline, two months, and yearly
ntervals throughout the five-year study. Outcome was
nalyzed both by an intention-to-treat analysis and accord-
ng to the presence or absence of AF during follow-up. No
ifferences were found in baseline characteristics of the
ubstudy population in those assigned randomly to a rate
ontrol (125 patients) or rhythm control (120 patients)
trategy. Most patients were older (mean age, 70 years), had
reserved left ventricular function (mean left ventricular
jection fraction, 51%) and were taking warfarin (93%).
At the conclusion of the substudy, 36% of patients in the
ate control arm were in sinus rhythm compared with 65%
n the rhythm control arm. Although there was no differ-
nce in NYHA functional class in the rate control compared
ith the rhythm control group, the presence of sinus
hythm throughout the study carried a small-but-
tatistically significant improvement in NYHA functional
lass. Patients assigned randomly to the rhythm control
roup were able to walk a mean of 94 feet further on the
-min walk test compared with those in the rate control
roup. However, in the on-treatment analysis, the presence
f sinus rhythm was not associated with an overall improve-
ent in 6-min walk time despite the finding that the mean
eart rate in the AF group was significantly higher both
efore and after the 6-min walk by approximately 12
eats/min. There was no difference in mental status between
roups.
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November 15, 2005:1900–1 Editorial CommentShould we now embrace rhythm control as the preferred
trategy in patients with AF and functional limitations?
learly this study falls short of allowing any definitive
ecommendation. Although the improvement in NYHA
unctional class was statistically significant, careful exami-
ation of the y-axis in Figure 1B in the paper by Chung et
l. (7) reveals that the overall improvement in functional
lass was only 0.15, an improvement of limited clinical
enefit. It would be helpful to know whether a subgroup of
atients with severe limitations at baseline would derive a
reater benefit from sinus rhythm, but the number of
atients in this substudy was not large enough to allow more
etailed analysis. As the authors discussed, the improvement
n 6-min walk of 94 feet is on par with improvements
bserved in therapies such as biventricular pacing for con-
estive heart failure (10,11). However, if the improvement
as due to the maintenance of sinus rhythm, one would
xpect the on-treatment analysis to show an even greater
enefit for those patients maintaining sinus rhythm. Yet, no
enefit was shown. An early benefit seemed to occur in the
rst two years in the sinus rhythm group but then waned by
he end of the study. The reason for this lack of benefit is
nclear; however, the limited symptomatology and lack of
tructural heart disease in the AFFIRM trial population
ay have limited the ability to find dramatic differences in
unctional status between the two groups. Similarly, the
igh rate of warfarin use may have limited the ability to
etect any difference in mental status between the groups.
Another recent study also examined functional status in
atients with AF. The Sotalol Amiodrone Atrial Fibrilla-
ion Efficacy Trial (SAFE-T) randomized 655 patients with
ersistent AF to receive amiodarone, sotalol, or placebo
12). Although the primary outcome of the trial was
aintenance of sinus rhythm, functional status and quality
f life were prespecified secondary end points. After one
ear of treatment, the patients maintaining sinus rhythm
ad significant improvements in three of eight quality of life
cores measured by the Short Form-36 questionnaire. Pa-
ients in sinus rhythm also had a greater improvement in
xercise duration at one year compared with patients re-
aining in AF (77.9 s vs. 14.6 s; p  0.02).
How do we make use of these findings in clinical
ractice? In the end, although the rate and rhythm control
trategies are often framed as opposing viewpoints (13), the
wo strategies often are complementary. We learned from
he AFFIRM trial that in older, asymptomatic patients with
F, a rate control strategy often is preferable to the side
ffects and toxicity of antiarrhythmic drug therapy and
ultiple cardioversions. For patients with severe symptoms
hile in AF, a rhythm control strategy is mandatory. The
ata from Chung et al. (7) and the SAFE-T trial support
he notion that maintenance of sinus rhythm also may help
atients with functional limitations while in AF. The ideal
trategy for the young asymptomatic patient or those with
ild symptoms remains unclear. Certainly the cumulativeifetime effect of persistent AF on a 35-year-old patient ismpossible to ascertain from the five-year follow-up in the
FFIRM study. If a safe, effective method for achieving
ong-term sinus rhythm maintenance was available widely,
ost would opt for it. Whether the promise of atrial specific
ntiarrhythmic drugs (14) or improvements to nonpharma-
ologic therapies will meet these goals remains to be seen.
or now, clinical judgment and further studies like those by
hung et al. (7) are our best tools for guiding treatment of
ur patients with AF.
eprint requests and correspondence: Dr. Edward P. Gersten-
eld, Hospital of the University of Pennsylvania, 9 Founders
avilion, 3400 Spruce Street, Philadelphia, Pennsylvania 19104.
-mail: edward.gerstenfeld@uphs.upenn.edu.
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